Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 9/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18717652 | 0.88 | KDM4E (0.46) | KDM4EHSD17B10HPGDMEN1USP2 | |
| SCHEMBL18694129 | 0.82 | HSD17B10 (0.53) | KDM4EHSD17B10HPGDMEN1USP2 | |
| SCHEMBL18694396 | 0.80 | HPGD (0.60) | KDM4EHSD17B10HPGDMEN1USP2 | |
| SCHEMBL18704450 | 0.78 | GRM1 (0.47) | KDM4EHSD17B10HPGDGRM5GRM1 | |
| SCHEMBL16597846 | 0.76 | TNK2 (0.50) | GRM5GRM1PDK4 | |
| SCHEMBL18694033 | 0.75 | JAK1 (0.42) | PDK4ELANEJAK1 | |
| SCHEMBL18692286 | 0.74 | GRM1 (0.47) | GRM5GRM1PDK4CFTRJAK1 | |
| SCHEMBL16112803 | 0.74 | PDK4 (0.61) | GRM5GRM1PDK4MEN1KMT2A | |
| SCHEMBL28514156 | 0.74 | GRM1 (0.49) | GRM5GRM1PDK4CFTRJAK1 | |
| SCHEMBL18694310 | 0.74 | CFTR (0.63) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| WO-2017060873-A1 | SUBSTITUTED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXYLIC ACIDS AND THEIR USE | AbbVie S.à.r.l. (LU) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | KDM4E 4749/4885HSD17B10 3762/4885HPGD 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.